Q&A: Poolbeg Pharma on target for $1bn cancer opportunity

Name: Q&A: Poolbeg Pharma on target for $1bn cancer opportunity
Uploaded: 2024-01-17T07:28:03.730261+00:00
Duration: 432 s
Channel: Vox Markets

125 views

1 year ago

Author: Vox Markets

Vox Markets talks to Poolbeg Pharma CEO Jeremy Skillington and Chief Business Office David Allman about the latest positive results for its lead asset POLB 001 which could help it tap into what could be a $1bn market opportunity in cancer immunotherapy.

0:30 How the latest in vivo trial results …

Equities

Money

AIM

Investing

Stock Market

Stocks to Follow

Main Market

Stocks

POLB

Poolbeg

POLB 001

immunotherapy